注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Aquestive Therapeutics Inc是一家製藥公司。該公司從事開發口服給藥產品以傳遞分子,提供護理療法的替代品。該公司致力於推進以治療中樞神經系統(CNS)疾病為重點的後期產品線,以及用於治療包括過敏反應在內的嚴重過敏反應的早期產品線。該公司專注於癲癇的CNS產品組合包括Sympazan和Libervant。其複雜分子管道產品組合中的活躍項目有:AQST-109-SF、AQST-108-SF和AQST-108-SF。其PharmFilm技術開發的藥物可提供無創給藥、為吞嚥困難患者量身定制的適用性,無需水即可給藥,並確保一致的治療劑量。PharmFilm由用作成膜劑的聚合物組合物組成,可將活性藥物成分(API)和賦形劑固定在適當的位置。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Gregory Bailey Brown | 71 | 2007 | Independent Director |
John Shannon Cochran | 58 | 2004 | Independent Vice Chairman of the Board |
Daniel Barber | 48 | 2014 | CEO, President & Director |
Jay Lieberman | - | 2022 | Member of Scientific Advisory Board |
Santo J. Costa | 78 | 2015 | Independent Chairman of the Board |
Timothy E. Morris | 63 | 2022 | Independent Director |
Julie Krop | 58 | 2021 | Independent Director |
David B. Golden | - | 2022 | Member of Scientific Advisory Board |
David M. Fleischer | - | 2022 | Member of Scientific Advisory Board |
John Oppenheimer | - | 2022 | Member of Scientific Advisory Board |
David I. Bernstein | - | 2022 | Member of Scientific Advisory Board |
Marco Taglietti | 64 | 2021 | Independent Director |
Ruchi S. Gupta | - | 2022 | Member of Scientific Advisory Board |
Matthew Greenhawt | - | 2022 | Member of Scientific Advisory Board |
Carlos Camargo | - | 2022 | Member of Scientific Advisory Board |
Abigail L. Jenkins | 48 | 2024 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核